Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06859424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Study acronym: ACCELERATE
StatusRecruiting
PhasePhase 2
Started2025-07-25
View on ClinicalTrials.gov ↗

Amendment history

2026-03-16
minor
Study Status, Oversight, Contacts/Locations v4
Study sites3→13
2025-09-03
minor
Study Status, Contacts/Locations v3
Start dateestimated 2025-07→confirmed 2025-07-25
Study sites2→3
2025-07-25
notable
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2025-06→2025-07
Study sites0→2
Study titlerevised
[...] ide-Based Graft-Versus-Host Disease Prophylaxis in Patients withWith Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
2025-03-10
minor
Study Status, Study Design, Arms and Interventions, Outcome Measures v1
Secondary endpointsdetails revised at 1 of 14 entries
2025-02-28
minor
Original filing
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Trial Details
NCT Number NCT06859424
Lead Sponsor Center for International Blood and Marrow Transplant Research
Collaborators: National Marrow Donor Program, Incyte Corporation
Conditions AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML) +3 more
Enrollment 358 participants
Start Date 2025-07-25
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-17